紫杉醇联合顺铂腹腔和静脉双途径治疗晚期卵巢癌的临床疗效观察  

Clinical Efficacy of Paclitaxel Combined with Intraperitoneal Cisplatin and Venous Approaches in the Treatment of Advanced Ovarian Cancer

作　　者：朱慧敏[1] Zhu Huimin(Department of Obstetrics and Gynecology, No.3 Affiliated Hospital of Luohe MedicalCollege, Luohe 462000)

机构地区：[1]漯河医学高等专科学校第三附属医院妇产科

出　　处：《数理医药学杂志》2019年第8期1198-1199,共2页Journal of Mathematical Medicine

摘　　要：目的:观察晚期卵巢癌用紫杉醇联合顺铂腹腔和静脉双途径治疗效果。方法:抽取2017年7月~2018年8月某院收治的66例晚期卵巢癌患者作为研究对象,分析所有患者病例资料,通过不同的治疗措施将66例患者分为对照组与观察组各33例。对照组行紫杉醇治疗,观察组行紫杉醇联合顺铂腹腔和静脉双途径治疗,对比两组CA125控制有效率、不良反应发生率、临床疗效。结果:CA125控制有效率、临床疗效与对照组相比,观察组较高,P<0.05;不良反应发生率与对照组比较,观察组较低,P<0.05。结论:晚期卵巢癌用紫杉醇联合顺铂腹腔和静脉双途径治疗,不仅能提高CA125控制有效率与临床疗效,还可减少不良反应发生率,值得推广。Objective: To observe the effect of paclitaxel combined with intraperitoneal cisplatin and venous approaches in the treatment of advanced ovarian cancer. Methods: 66 patients with advanced ovarian cancer admitted to a hospital from July 2008 to August 1818 were enrolled. The patient data were analyzed. 66 patients were divided into control group and observation group according to the different treatments. The control group(33 cases) received paclitaxel treatment, and the observation group(33 cases) underwent paclitaxel combined with intraperitoneal cisplatin and venous approaches. The efficacy of CA125 control, the incidence of adverse reactions, and clinical efficacy were compared. Results: CA125 control efficiency and clinical efficacy were higher in the observation group than in the control group, P<0.05. The incidence of adverse reactions was lower in the observation group than in the control group, P<0.05. Conclusion: The treatment of paclitaxel combined with intraperitoneal cisplatin and venous approaches in the advanced ovarian cancer can not only improve the efficiency and clinical efficacy of CA125 control, but also reduce the incidence of adverse reactions, which is worthy of promotion.

关 键 词：晚期卵巢癌 紫杉醇 顺铂 腹腔 静脉 治疗效果 

分 类 号：R737.31[医药卫生—肿瘤]